JP2018522920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522920A5 JP2018522920A5 JP2018506932A JP2018506932A JP2018522920A5 JP 2018522920 A5 JP2018522920 A5 JP 2018522920A5 JP 2018506932 A JP2018506932 A JP 2018506932A JP 2018506932 A JP2018506932 A JP 2018506932A JP 2018522920 A5 JP2018522920 A5 JP 2018522920A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- gaboxadol
- administered
- composition according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims description 64
- 229950004346 gaboxadol Drugs 0.000 claims description 64
- 150000003839 salts Chemical class 0.000 claims description 54
- 239000008194 pharmaceutical composition Substances 0.000 claims description 51
- 206010039897 Sedation Diseases 0.000 claims description 42
- 230000036280 sedation Effects 0.000 claims description 42
- 238000001802 infusion Methods 0.000 claims description 20
- 206010002091 Anaesthesia Diseases 0.000 claims description 14
- 230000037005 anaesthesia Effects 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 12
- 230000001624 sedative effect Effects 0.000 claims description 8
- 239000000932 sedative agent Substances 0.000 claims description 3
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 230000000147 hypnotic effect Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 47
- 239000008177 pharmaceutical agent Substances 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203731P | 2015-08-11 | 2015-08-11 | |
| US201562203748P | 2015-08-11 | 2015-08-11 | |
| US62/203,748 | 2015-08-11 | ||
| US62/203,731 | 2015-08-11 | ||
| US14/834,027 | 2015-08-24 | ||
| US14/834,027 US9399034B1 (en) | 2015-08-11 | 2015-08-24 | Methods of sedation during critical care treatment |
| US15/185,650 US9717716B2 (en) | 2015-08-11 | 2016-06-17 | Methods of sedation during critical care treatment |
| US15/185,650 | 2016-06-17 | ||
| PCT/US2016/045094 WO2017027249A1 (en) | 2015-08-11 | 2016-08-02 | Methods of sedation and parenteral formulation for use during critical care treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522920A JP2018522920A (ja) | 2018-08-16 |
| JP2018522920A5 true JP2018522920A5 (enExample) | 2019-09-05 |
| JP6857647B2 JP6857647B2 (ja) | 2021-04-14 |
Family
ID=59687449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506932A Expired - Fee Related JP6857647B2 (ja) | 2015-08-11 | 2016-08-02 | クリティカル・ケア処置中に用いるための鎮静方法および非経腸製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180235942A1 (enExample) |
| EP (1) | EP3334427A4 (enExample) |
| JP (1) | JP6857647B2 (enExample) |
| KR (1) | KR20180048707A (enExample) |
| CN (1) | CN108135889A (enExample) |
| AU (1) | AU2016304737B2 (enExample) |
| CA (1) | CA2994952A1 (enExample) |
| CO (1) | CO2018002534A2 (enExample) |
| IL (1) | IL257296B2 (enExample) |
| MX (1) | MX394213B (enExample) |
| PE (1) | PE20181332A1 (enExample) |
| TW (1) | TWI763632B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016295138B2 (en) | 2015-07-17 | 2021-11-04 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| US20180042903A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| WO2020061410A1 (en) | 2018-09-20 | 2020-03-26 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering |
| MX2021005992A (es) | 2018-11-21 | 2021-09-14 | Certego Therapeutics Inc | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. |
| JP2022514275A (ja) | 2018-12-17 | 2022-02-10 | オービッド・セラピューティクス・インコーポレイテッド | 非２４時間型睡眠覚醒障害の処置のためのガボキサドールの使用 |
| IL298334A (en) | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| US20220218740A1 (en) * | 2020-10-25 | 2022-07-14 | Vaporworks Nursing Anesthesia Inc. | Opioid-free compositions for anesthesiological applications and related methods and systems |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071933A (en) * | 1999-12-03 | 2000-06-06 | Diversified Medical Innovations, Inc. | Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use |
| US20050215521A1 (en) * | 2003-12-22 | 2005-09-29 | Karim Lalji | Modafinil combination therapy for improving sleep quality |
| EP1742624B1 (en) * | 2004-02-18 | 2010-01-06 | Sepracor, Inc. | Dopamine-agonist combination therapy with sedatives for improving sleep quality |
| US20090143335A1 (en) * | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| US9399034B1 (en) * | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
-
2016
- 2016-08-02 EP EP16835628.5A patent/EP3334427A4/en not_active Withdrawn
- 2016-08-02 KR KR1020187007146A patent/KR20180048707A/ko not_active Withdrawn
- 2016-08-02 AU AU2016304737A patent/AU2016304737B2/en not_active Ceased
- 2016-08-02 PE PE2018000199A patent/PE20181332A1/es not_active Application Discontinuation
- 2016-08-02 US US15/751,680 patent/US20180235942A1/en not_active Abandoned
- 2016-08-02 MX MX2018001720A patent/MX394213B/es unknown
- 2016-08-02 JP JP2018506932A patent/JP6857647B2/ja not_active Expired - Fee Related
- 2016-08-02 CA CA2994952A patent/CA2994952A1/en active Pending
- 2016-08-02 CN CN201680059253.3A patent/CN108135889A/zh active Pending
- 2016-08-10 TW TW105125498A patent/TWI763632B/zh not_active IP Right Cessation
-
2018
- 2018-02-01 IL IL257296A patent/IL257296B2/en unknown
- 2018-03-09 CO CONC2018/0002534A patent/CO2018002534A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522920A5 (enExample) | ||
| JP2014528474A5 (enExample) | ||
| CA2709997A1 (en) | Pirfenidone treatment for patients with atypical liver function | |
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP2014515373A5 (enExample) | ||
| BRPI0707235B1 (pt) | formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| KR100516676B1 (ko) | 안면 수술에서의 레보부피바카인의 용도 | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2013541583A (ja) | 組み合わせ組成物 | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| Kim et al. | Comparison of palonosetron with ondansetron in prevention of postoperative nausea and vomiting in patients receiving intravenous patient-controlled analgesia after gynecological laparoscopic surgery | |
| JP2019512495A5 (enExample) | ||
| JP2012502047A5 (enExample) | ||
| JP2016521755A5 (enExample) | ||
| JP2020500864A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2011500589A5 (enExample) | ||
| WO2012044783A8 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| Bolliger et al. | A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy | |
| MX2021008208A (es) | Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| JP2012502105A5 (enExample) | ||
| Lee et al. | Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients |